ArticleBioMed research international2026
Aqueous Extract of Opuntia ficus-indica (L. Mill) Cladodes Demonstrates Antidiabetic Effect in Normoglycemic and STZ-Induced Diabetic Rats.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aqueous Extract of Opuntia ficus-indica (L. Mill) Cladodes Demonstrates Antidiabetic Effect in Normoglycemic and STZ-Induced Diabetic Rats.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOpuntia ficus-indica (L. Mill) cladode is traditionally used for food and for the management of diabetes mellitus (DM), but its scientific basis and mechanisms remain underexplored.
objectiveThe study assessed antidiabetic effects and mechanisms of action of O. ficus-indica aqueous extract (OFIAE).
methodsFresh cladodes were blended, centrifuged, and filtered to obtain OFIAE. Phytochemical profiling used colorimetric methods. Antidiabetic potential was evaluated via (1) oral glucose tolerance test (OGTT) in normoglycemic Sprague-Dawley rats pretreated with OFIAE (4, 40, and 400 mg/kg, p.o.), metformin, or none; (2) glucose uptake assay in yeast cells with glucose (5, 10, and 25 mM) ± OFIAE (125-1250 μg/mL); and (3) in vitro α-amylase and α-glucosidase inhibition. Experimental diabetes was induced in male Sprague-Dawley rats (STZ-nicotinamide; fasting blood glucose [FBG] > 11 mmol/L). Diabetic rats were treated orally for 28 days with OFIAE (4, 40, and 400 mg/kg), metformin (300 mg/kg), or vehicle. Body weight and FBG were recorded weekly. Glycated hemoglobin (HbA1c) was measured posttreatment. Liver (PAS and H&E) and pancreas (H&E and insulin immunostaining) were histologically examined.
resultsOFIAE contained flavonoids, alkaloids, and phenolic compounds. OFIAE significantly reduced postprandial blood glucose during OGTT compared to control. It enhanced glucose uptake in yeast and inhibited α-amylase (IC
conclusionOFIAE exhibits antihyperglycemic effects by inhibiting carbohydrate-digestive enzymes (α-amylase and α-glucosidase), enhancing peripheral glucose uptake, increasing insulin secretion, and promoting hepatic glycogen storage. These findings validate its traditional use and highlight its potential as a complementary therapy for Type 2 DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.